Junevity Inc. has raised $10 million in new funding, bringing its seed financing to a total of $20 million. The new funding will enable Junevity to advance JUN-01, its lead siRNA program for type 2 diabetes and obesity, through IND-enabling and initial clinical studies.
Animate Biosciences Inc. has released new preclinical results demonstrating that AI-designed peptides generated by its Animateiq discovery platform significantly reduced hallmark inflammation and fibrosis signals across multiple human cell types, including skin, lung, heart and liver.
Arrakis Therapeutics Inc. has announced the presentation of preclinical data demonstrating the progress of its RNA-targeted small molecule (rSM) drug program for the treatment of myotonic dystrophy type 1 (DM1).
Shenzhen Forward Pharmaceuticals Co. Ltd. has described fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of stomach cancer and intrahepatic cholangiocarcinoma.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has divulged cellular tumor antigen p53 (TP53) (Tyr220Cys mutant) stabilizers reported to be useful for the treatment of cancer.
Apichope Bio Pharmaceutical Co. Ltd., Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have synthesized xanthine dehydrogenase/oxidase (XDH; XOR) inhibitors reported to be useful for the treatment of hyperuricemia, gout, arthritis and heart failure.
Theratechnologies Inc. and Transfert Plus SEC have disclosed peptide-drug conjugates comprising a maytansinoid moiety linked to peptides targeting the sortilin (neurotensin NTR3; NT3; Gp95) receptor through a protease-cleavable linker reported to be useful for the treatment of cancer.
Neuroblastoma is a pediatric extracranial solid tumor arising from the sympathetic nervous system. Disialoganglioside GD2-based therapies, including CAR T cells and other immunotherapies, have shown some success. However, GD2 is also expressed on pain fibers and other neurons, raising safety concerns, and relapses after anti-GD2 therapy are frequent.
RSS
